Andrew Weil - Teva Pharmaceutical Chief Accounting Officer
| TEVA Stock | ILA 6,340 20.00 0.32% |
Insider
Andrew Weil is Chief Accounting Officer of Teva Pharmaceutical Industries since 2021.
| Age | 52 |
| Tenure | 3 years |
| Phone | (972) 3 914 8213 |
| Web | www.tevapharm.com |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Haim Delmar | Elbit Systems | 49 | |
| Raja Dakkuri | Bank Leumi Le Israel | 52 | |
| Ilan Sigal | Bezeq Israeli Telecommunication | 48 | |
| Eyal BenHaim | Bank Leumi Le Israel | 52 | |
| Yaacov Kagan | Elbit Systems | N/A | |
| Iris Avner | Tower Semiconductor | 54 | |
| Meni Baruch | Bezeq Israeli Telecommunication | 48 | |
| Amit Kurland | Bezeq Israeli Telecommunication | 52 | |
| Tobi Fischbein | Bezeq Israeli Telecommunication | 50 | |
| Noit LevyKaroubi | Tower Semiconductor | 38 | |
| Oren Cohen | El Al Israel | N/A | |
| Avraham Ortal | Bank Leumi Le Israel | 56 | |
| David Paulson | Bank Leumi Le Israel | 60 | |
| Rami Myerson | Elbit Systems | N/A | |
| Yoav Chelouche | Tower Semiconductor | 66 | |
| Eliav David | Bank Leumi Le Israel | N/A | |
| Ziv CPA | Bank Leumi Le Israel | 52 | |
| Jerry Neal | Tower Semiconductor | 74 | |
| Avivit Klein | Bank Leumi Le Israel | 54 | |
| Zvika Abramovich | Bezeq Israeli Telecommunication | N/A | |
| Yizhak Eliav | El Al Israel | 48 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nechemia Peres, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Janet Vergis, Independent Director | ||
| Amir Weiss, VP Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Ex Portfolio | ||
| Abbas Hussain, Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
| Kathleen Veit, Global VP | ||
| Deborah Griffin, Chief Accounting Officer | ||
| Perry Nisen, Independent Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Kevin Mannix, Vice President Head of Investor Relations | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Andrew Weil, Chief Accounting Officer | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 102.13 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 2.32 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.